HR+/HER2- advanced breast cancer treatment patterns in China
Part of Cancer, Skin clinical trials.
This study looks at the real-world treatment patterns and outcomes for people with HR+/HER2- advanced breast cancer who started their first treatment in China between 2024 and 2027. It aims to understand what treatments are used and how well they work in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HR+/HER2- advanced breast cancer (meaning your cancer cells have hormone receptors and not too much HER2 protein).
- You started your first treatment for advanced breast cancer on or after January 1, 2024, and before January 1, 2027.
- You were 18 years or older when you started that first treatment.
- You have had at least 3 months of follow-up visits with your doctor after starting that treatment.
- You do not have any other active invasive cancer (other than breast cancer) now, or within the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how doctors in China treat hormone receptor-positive, HER2-negative breast cancer that has spread, when patients are starting their second line of therapy. The goal is to learn more about real-world treatment patterns and results, which may help you and your doctor make more informed treatment decisions.
This trial is looking at how neratinib is used as extended treatment after early-stage HER2+ breast cancer, and how it affects patient outcomes in real-world care. You might qualify if you’re an adult with HER2+ early breast cancer that doctors consider free of recurrence and metastasis, and you’re able to take neratinib as prescribed in China.
This trial looks at how well a standard “neoadjuvant” treatment plan works in real-world patients. It is for people newly diagnosed with stage II–III HR+ breast cancer and aims to see whether treatment gives expected outcomes in everyday care.
This study looks at how Chinese patients with a specific gene change (ESR1 mutation) in ER-positive, HER2-negative advanced breast cancer are currently being treated. It will help doctors understand what treatments work best for people whose cancer has stopped responding to hormone therapy.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
Hear when a new HR+/HER2- Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.